Taysha Gene Therapies TSHA
NASDAQ TSHA
$4.74 -0.13 (-2.67%)
At close: Oct 1, 2026 · 4:00 PM EDT

Taysha Gene Therapies (TSHA) Long-Term Debt Repayments (2020)

Updated

Taysha Gene Therapies' Long-Term Debt Repayments was $1.67 million in FY2020.

Analysis

Taysha Gene Therapies (TSHA) Long-Term Debt Repayments (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 2.00 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 5.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -2.45 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 17.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Taysha Gene Therapies 1.58 Bn 1.58 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 28,000.00
Jun 30, 2020 -1,000.00
Mar 31, 2020 1.65 Mn
API Access

Taysha Gene Therapies Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=TSHA&period=max&api_key=YOUR_API_KEY